Patent · US Active

Combined treatment with netrin-1 interfering drug and chemotherapeutic drug

US9895439B2 · kind B2 · utility

0Cited by
3References
4Claims
0Family size

Assignee

Inventors

Key dates

Filing dateSep 12, 2013
Grant dateFeb 20, 2018
Priority date
Expiry dateSep 12, 2033

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2319/30
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Pharmaceutical composition comprising a chemotherapeutic drug and a netrin-1 interfering drug or a vector capable of expressing a netrin-1 interfering drug in vivo, in a pharmaceutically acceptable carrier or vehicle. The chemotherapeutic drug is selected from those able to induce over expression of netrin-1 in cancer cells. The combination is associated with synergic anti-cancer effect.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.